Severe acute respiratory syndrome vaccine - Protein Sciences
Alternative Names: D-3252; SARS vaccine - Protein Sciences; SARS-CoV spike protein vaccine - Protein SciencesLatest Information Update: 28 Dec 2017
At a glance
- Originator Protein Sciences Corporation
- Class COVID-19 vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Severe acute respiratory syndrome
Most Recent Events
- 28 Dec 2017 No recent reports of development identified for preclinical development in Severe acute respiratory syndrome(Prevention) in USA (Parenteral)
- 28 Aug 2017 Protein Sciences Corporation has been acquired by Sanofi
- 07 Dec 2015 The Severe acute respiratory syndrome vaccine is still in active development